Rigel Pharmaceuticals | RIGL - Selling And Administration Expenses


Rigel Pharmaceuticals reported $27.04M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
Agenus USD 10.56M 13.04M Dec/2025
Amgen USD 1.58B 354M Mar/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 41.74M 4.28M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Celldex Therapeutics USD 11.45M 3.61M Mar/2026
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
Halozyme Therapeutics USD 46.29M 18.35M Mar/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Intrexon USD 10.31M 41K Jun/2024
Ionis Pharmaceuticals USD 151M 21M Mar/2026
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
Ligand Pharmaceuticals USD 20.84M 4.19M Mar/2026
MacroGenics USD 9.71M 1.77M Mar/2026
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Veracyte USD 50.84M 7.53M Mar/2026